Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- DKK | -.--% | -.--% | -0.50% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stacy Wheeler
COO | Chief Operating Officer | - | 16-02-29 |
Chief Tech/Sci/R&D Officer | - | 17-09-12 | |
Lionel Rostaing
PRN | Corporate Officer/Principal | - | - |
Josep Grinyo
PRN | Corporate Officer/Principal | - | - |
Noel Barnard
LAW | General Counsel | - | 16-02-29 |
Mark Hensley
PRN | Corporate Officer/Principal | - | 16-03-31 |
Rita L. Mannella
HRO | Human Resources Officer | - | 16-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,739,741,590 | 173,932,405 ( 9.998 %) | 0 | 9.998 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Asahi Kasei Corp., Veloxis Pharmaceuticals, Inc. manufactures pharmaceuticals for kidney transplant patients. The private company is based in Edison, NJ. |
Pharmaceuticals: Major
|
Sector
1st Jan change | Capi. | |
---|---|---|
-0.50% | 1.64B | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- VELO Stock
- Company Veloxis Pharmaceuticals A/S